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HAMLET is a complex of human -lactalbumin (ALA) and
oleic acid and kills several Gram-positive bacteria by a mecha-
nism that bears resemblance to apoptosis in eukaryotic cells. To
identify HAMLET’s bacterial targets, here we used Streptococ-
cus pneumoniae as amodel organismand employed a proteomic
approach that identified several potential candidates. Two of
these targets were the glycolytic enzymes fructose bisphosphate
aldolase (FBPA) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH). Treatment of pneumococci with HAMLET
immediately inhibited their ATP and lactate production, sug-
gesting that HAMLET inhibits glycolysis. This observation was
supported by experiments with recombinant bacterial enzymes,
along with biochemical and bacterial viability assays, indicating
that HAMLET’s activity is partially inhibited by high glucose–
mediated stimulation of glycolysis but enhanced in the presence
of the glycolysis inhibitor 2-deoxyglucose. Both HAMLET and
ALA bound directly to each glycolytic enzyme in solution and
solid-phase assays and effectively inhibited their enzymatic
activities. In contrast, oleic acid alone had little to no inhibitory
activity. However, ALA alone also exhibited no bactericidal
activity and did not block glycolysis in whole cells, suggesting a
role for the lipid moiety in the internalization of HAMLET into
the bacterial cells to reach its target(s). This was verified by inhi-
bition of enzyme activity in whole cells after HAMLET but not
ALA exposure. The results of this study suggest that part of
HAMLET’s antibacterial activity relates to its ability to target
and inhibit glycolytic enzymes, providing an example of a natu-
ral antimicrobial agent that specifically targets glycolysis.
HAMLET3 (Human alpha-lactalbuminmade lethal to tumor
cells) consists of human -lactalbumin (ALA) in a partially
unfolded state, stabilized by binding the human milk–
specific fatty acid oleic acid (OA; C18:1 cis-9) (1). HAMLET
was first purified from human milk casein and shown to kill
tumor cells by induction of apoptosis, while sparing healthy
cells (2, 3). Part of HAMLET’s activity is related to its ability
to enter cancer cells and interact with mitochondria to
induce depolarization and permeability transition that leads
to apoptosis execution (4, 5). Using an shRNA-based screen
in tumor cells, Svanborg and collaborators (6) demonstrated
that glycolytic enzymes were required for full HAMLET
activity. It was therefore suggested that HAMLET interferes
with glycolysis tomediate a change in cancer cell metabolism
as part of its death induction.
HAMLET also kills several species of bacteria (the evolu-
tionary predecessor to mitochondria), with its highest activ-
ity against Streptococcus pneumoniae (7, 8), an aerotolerant,
anaerobic organism that lacks the Krebs’ cycle and oxidative
phosphorylation and relies primarily on glycolysis and fer-
mentation for energy production (9). Interestingly, akin to
features seen in eukaryotic cells, HAMLET-induced death in
bacteria is accompanied by depolarization of the bacterial
membrane that requires sodium-dependent calcium transport,
cell shrinkage, DNA condensation and fragmentation, and
other biochemical hallmarks of mitochondria-induced apopto-
sis (8, 10). These phenotypes are also present when these bac-
teria die from other physiological stimuli, such as starvation,
and represent a novel and general bacterial death mechanism
thatwe are currently exploring. This suggests that physiological
cell death pathways in prokaryotic and eukaryotic cells may be
more similar than previously considered.
Besides its direct antibacterial activity, HAMLET can also
potentiate the effect of antibiotics to render bacterial species
sensitive to antibiotics they are resistant to (11, 12). This effect
is not limited to species sensitive to HAMLET but can also be
seen for antibiotic-resistant organisms of species that are not
directly killed byHAMLET (12).HAMLET’s potentiating effect
was shown to also require ion transport and membrane depo-
larization, and HAMLET treatment resulted in an increased
binding/association of the antibiotics used to the bacterial pop-
ulation treated (12).
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In this study, we show that HAMLET disrupts glycolysis in
whole pneumococci and that this disruption is partially respon-
sible for, and clearly potentiates, HAMLET’s bactericidal activ-
ity. Unlike previous studies associating the bactericidal activity
of HAMLET with the OA component, this study showed that
the protein component (ALA) was responsible for HAMLET’s
inhibitory effect on glycolysis in whole cells. We show that
HAMLET binds to and inactivates two key glycolytic enzymes,
fructose-bisphosphate aldolase (FBPA) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), both in vitro and in vivo.
This inhibition results in an impaired production of ATP that
augments activation of HAMLET’s cell death mechanism. A
detailed understanding of HAMLET’s inhibition of glycolysis
could provide future leads to therapeutic intervention against a
broad range of bacterial species.
Results
Bactericidal activity of HAMLET, ALA, and oleic acid
HAMLETwas used to treat S. pneumoniaeD39 in a time-kill
assay over 1 h. This treatment caused a concentration-depen-
dent death of pneumococci with a 3 log10 reduction in bacterial
viability at100g/ml (6M) and eradication of the inoculum
reached at 250 g/ml (15 M). (Fig. 1, solid line). As HAMLET
is a complex of ALA and oleic acid, we also tested each compo-
nent separately. Native ALA had no bactericidal activity (Fig. 1,
dashed line), and we know from previous experience that no
death occurs even after exposure to 10,000 g/ml (7, 10). OA,
however, has been shown to have bactericidal activity by itself
(13).MeasurementsofHAMLET/OAstoichiometryconsistent-
ly show a molar ratio of 1:5 (14, 15) with OA constituting
9–11% of the total complexweight. To understand the role of
OA in the bactericidal activity of HAMLET, we treated the bac-
teria with OA at the concentration present in the complex
(based on a 10% (w/w) OA content). Although OA had bacte-
ricidal activity by itself, the concentration associated with var-
ious concentrations ofHAMLETcomplex consistently resulted
in significantly lower bactericidal activity than the HAMLET
complex itself (Fig. 1, dotted line). These results suggest that
although lipid is required for HAMLET’s bactericidal activity,
both ALA and OA are necessary and contribute to bacterial
killing.
HAMLET inhibits glycolysis and ATP production in
pneumococci
To investigate the role of HAMLET treatment on glycolysis
activity and ATP production, D39 pneumococci were washed
and resuspended in PBS without any carbon source. At T  0
min, the bacteria were energized by adding 10 mM glucose, and
at T  5 min or T  10 min, 125 g/ml HAMLET (a concen-
tration that resulted in a 4 log10 reduction in viability over 1 h)
was added to subsets of energized bacteria, and lactate secre-
tion from the cells and ATP content in the cells were measured
over time (Fig. 2, A and B). HAMLET addition resulted in an
immediate and drastic inhibition of both ATP and lactate pro-
duction over time, resulting in significantly lower ATP accu-
mulation and lactate production in the cells at the 30-min time
point (Fig. 2).
To make sure that this was not just an effect of the bacteria
dying rapidly in the presence of high concentrations of HAM-
LET, the cells were treated with sublethal concentrations of
HAMLET (25, 37.5, and 50g/ml). HAMLETwas added 5min
after energizing the cells with glucose, and ATP content of the
bacteria was measured (Fig. 2C). No effect was seen for the
lowest HAMLET concentration, but both 37.5 and 50 g/ml
HAMLET significantly reduced theATPproduction in the cells
after 30min of incubation (p 0.05 and p 0.01 for 37.5 and 50
g/ml, respectively).
Treatment with native ALA had no effect on either ATP or
lactate production (Fig. 2, A and B). Similarly, the addition of
12.5g/mlOA (equivalent to the amount of lipid present in 125
g/ml HAMLET that resulted in a 2 log10 reduction in bac-
terial viability) did not significantly affect ATP production in
the pneumococci (Fig. 2D), suggesting that bacterial death
induced by OA was not directly associated with inhibition of
glycolysis or energy production.
Modulation of glycolysis function affects pneumococcal
sensitivity to HAMLET
We next addressed the role of HAMLET on glycolysis by
testing HAMLET’s activity in the presence of a high concentra-
tion of glucose that would accelerate glycolysis or in the pres-
ence of 2-deoxyglucose, a glucose analog that competitively
inhibits glycolysis as it cannot be hydrolyzed for energy. Bac-
terial cells in buffer alone (PBS) served as a control. None of
the treatments had any impact on bacterial survival by them-
selves over the 1-h time course of the assay. HAMLET was
added at increasing concentrations and incubated for 1 h at
Figure 1. Bactericidal activity of HAMLET, ALA, and oleic acid. S. pneu-
moniae D39 was treated with native ALA and HAMLET at the concentrations
indicated or with OA using a concentration equivalent to the concentration
present in HAMLET (10%, w/w) and incubated for 1 h at 37 °C. Viable organ-
isms were assessed after plating dilutions of each sample onto blood agar
plates and enumerating cfu after overnight growth. The results represent six
individual experiments and are presented as the mean with error bars repre-
senting the S.D. Statistical analysis was performed using Student’s unpaired t
test (*, p 0.05; ***, p 0.001; ns, nonsignificant).
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37 °C, and viability was monitored by viable plate counts
(Fig. 3A). The addition of glucose in the buffer significantly
reduced HAMLET-induced death at all concentrations
tested, with 1.3 log10 less death occurring at the highest con-
centration compared with cells treated in the absence of car-
bohydrate (p 0.01) and 2.7 log10 less death compared with
cells treated with the glycolysis inhibitor 2-deoxyglucose
(p  0.01), indicating that modulation of glycolysis activity
affects HAMLET’s bactericidal activity.
Treatment with bactericidal concentrations of OA was not
affected by the presence of glucose or 2-deoxyglucose in the
medium (Fig. 3B), again suggesting that OA-induced death
does not act by directly regulating glycolytic activity and energy
production in the pneumococcal cells.
HAMLET binds to FBPA and GAPDH
To identify potential bacterial targets responsible for HAMLET’s
glycolytic inhibition, we first separated bacterial lysate from
strain D39 by one-dimensional SDS-PAGE, transferred it to
nitrocellulose membrane, and overlaid the blot with biotiny-
lated HAMLET (biotinylation did not affect HAMLET’s bac-
tericidal activity, as shown in Fig. S1). Several bands were
identified as potential interaction partners for HAMLET
(Fig. 4A), and the identities of the two strongest bands were
determined by N-terminal sequencing using Edman degra-
dation. Only FBPA (31.4 kDa) and GAPDH (35.9 kDa) were
possible candidate proteins based on the N-terminal se-
quence data and on having appropriate molecular mass in
the blot (Fig. 4A).
In a second approach, biotinylated HAMLET conjugated
with NHS-LC-Diazirine, a UV-excitable cross-linker, was
added to pneumococcal cell lysate. After incubation, the
reactions were cross-linked by UV light, HAMLET and its
bound targets were captured on streptavidin-conjugated
magnetic beads, and captured proteins were identified by
LC-MS/MS. Two independent assays were performed, and
the results of the assay confirmed three peptides and one
peptide, respectively, with perfect match for FBPA and eight
peptides and five peptides, respectively, with perfect match
for GAPDH in experiments 1 and 2. As the identification of
captured proteins was performed by independent peptide
sequencing, the identity will have99.9% certainty if two or
more peptides are identified (ProtTech). In conclusion, both
assays identified two central enzymes in glycolysis (FBPA
and GAPDH) as potential HAMLET targets.
To ensure a direct interaction between HAMLET and the
two glycolytic proteins, pneumococcal, recombinant FBPA
and GAPDH were produced and separated by SDS-PAGE,
transferred to nitrocellulose, and overlaid with biotinylated
HAMLET or ALA. Interestingly, both HAMLET and ALA
(which had no effect on cell viability, ATP, or lactate produc-
tion) bound strongly to FBPA andGAPDH (Fig. 4B). Binding of
GAPDH and FBPA to HAMLET was also observed in solution
after capturing theHis-tagged enzymes bymagnetic beads (Fig.
S2). To confirm that HAMLET’s interaction with FBPA and
GAPDH was specific, binding assays employing the glycolytic
enzyme glucokinase (GK; also known as hexokinase) and dihy-
drolipoamide dehydrogenase (DLDH; the E3 component of
2-oxo acid dehydrogenases) were performed in solution. No
binding was observed to glucokinase; however, some binding
was observed to DLDH (Fig. S2).
Figure 2. Inhibition of glycolysis and energy production inHAMLET-treated S. pneumoniae. S. pneumoniaeD39were energizedwith 10mMglucose and
treated with 125 g/ml ALA after 5 min or 125 g/ml HAMLET after either 5 or 10 min (see arrows), and intracellular ATP production (A) and lactate secretion
(B) were recorded over time. C, D39 pneumococci were energized with 10 mM glucose and treated with sublethal concentrations of HAMLET (25, 37, and 50
g/ml) that were added 2min after the addition of glucose. D, D39 pneumococci were energized with 10mM glucose and treated with the OA concentration
present in 125g/ml HAMLET (12.5g/ml) that was added after either 5 or 10min. All results represent three individual experiments with duplicate samples
and are presented as themeanwith error bars representing the S.D. Statistical analysis was performed using Student’s unpaired t test (*, p 0.05; **, p 0.01;
***, p 0.001; ns, nonsignificant).
Pneumococcal glycolysis inhibition by HAMLET
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HAMLET specifically inhibits FBPA and GAPDH enzymatic
activity
AsHAMLETbound strongly to FBPA andGAPDH, two cen-
tral glycolysis enzymes, we were interested in investigating
whether this binding resulted in inhibition of their activity as a
mechanism of blocking ATP and lactate production. Recombi-
nant enzymes were assayed for enzymatic activity in the pres-
ence of increasing concentrations of HAMLET, ALA, and OA.
IgG was used as an unrelated protein control for comparison
(Fig. 5).
HAMLET and ALA both showed an effective inhibition of
FBPA activity with the IC50 being 2 g/ml for both proteins
and with over 75% of inhibition seen at a concentration of 8
g/ml. The inhibitory activity of OA was negligible, with
around 5% inhibition seen at the highest concentration tested,
which represents 80 g/ml HAMLET (8 g/ml OA; Fig. 5A).
IgG did not inhibit FBPA activity at all (Fig. 5A).
For GAPDH, the general inhibitory activity was somewhat
lower, with around 50% inhibition seen at 6 g/ml HAMLET
and around 40% inhibition seen for ALA at the same concen-
tration (Fig. 5B). OA inhibited GAPDH to a significantly lower
degree (22%; p  0.01 compared with HAMLET’s inhibitory
activity) at the concentration present in theHAMLET complex
(Fig. 5B). Again, IgG lacked any inhibitory activity. This indi-
cates thatHAMLET andALA show strong inhibitory activity of
both enzymes, whereas OA shows only a slight inhibitory activ-
ity against GAPDH.
HAMLET did not inhibit the activity of glucokinase even at
high concentrations (100 g/ml), which was consistent with a
lack of binding between the two proteins (Fig. S3A). Similarly,
even though HAMLET bound to DLDH, this binding was not
associatedwith any inhibitory activity even at concentrations of
HAMLET of up to 100 g/ml (Fig. S3B), suggesting that inter-
action in vitro does not automatically correlate with inhibitory
activity.
HAMLET but not ALA can access its target enzymes in vivo
Although ALA effectively inhibited both FPBA and GAPDH
activity in vitro (Fig. 5), it had no activity on the production of
ATP and lactate when added to whole cells (Fig. 2). This sug-
gested indirectly that HAMLET, but not ALA, may gain entry
to the bacterial cells and reach the respective targets to inhibit
glycolysis, similar to its ability to traverse the membrane and
enter tumor cells (4).
To provide further evidence that HAMLET directly targets
the glycolytic pathway intracellularly in vivo, we measured
FBPA activity in whole-cell extracts from D39 pneumococci
pretreated for 10min with various concentrations of HAMLET
and compared the activity with cells treated with ALA or OA
(Fig. 6). Cells were treated with HAMLET, ALA, OA, or
buffer alone for 10 min at 37 °C and were immediately
washed in 4 °C PBS to remove unassociated protein or lipid,
Figure 3. Modulation of glycolysis affects HAMLET sensitivity. D39 pneumococci were washed in PBS and resuspended in PBS alone or PBS with the
addition of either 25mM glucose or 25mM 2-deoxyglucose. After 15min, increasing concentrations of HAMLET (A) or oleic acid (B) were added to the bacterial
cells, and viable organisms were determined by viable counts after 1 h. All results represent three individual experiments with duplicate samples and are
presented as themeanwith error bars representing the S.D. Statistical analysis was performed using the Student’s unpaired t test (*, p 0.05; **, p 0.01; ***,
p 0.001; ns, nonsignificant).
Figure 4. Binding of HAMLET to FBPA and GAPDH. A, D39 whole bacterial
lysates were separated by SDS-PAGE and blotted to nitrocellulose mem-
brane. The blotwas blocked and incubated in the presence of buffer alone (S)
or biotinylated HAMLET (HL), and after the addition of HRP-conjugated
streptavidin, binding was detected in the presence of ECL reagents. The two
major bands detected were cut out and identified by Edman degradation. *,
presence of biotin carboxyl carrier protein (17.0 kDa), a protein that is natu-
rally biotinylated and thus reacts directly with the HRP-conjugated streptavi-
din and does not represent HAMLET binding. The blots were photographed
and are displayed without any image correction. B, pneumococcal recombi-
nant FBPA or GAPDH were separated by SDS-PAGE, blotted to nitrocellulose
membrane, and overlaid with HAMLET, ALA, or buffer alone (Streptavidin).
After incubation with HRP-conjugated streptavidin, binding was detected in
thepresenceof ECL reagents. Theblotswere capturedbyaGelDoc systemset
to automaticmode for optimal capture of signal in each blot image, andblots
are presented without image correction.
Pneumococcal glycolysis inhibition by HAMLET
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and bacterial lysates were produced. Lysates from cells
treated with ALA showed no significant change in FBPA
activity compared with untreated D39 pneumococci (FBPA
activity of 421 and 408 milliunits/mg for lysates from ALA-
treated and untreated bacteria, respectively). However, pre-
treatment of D39 pneumococci with HAMLET for 10 min
resulted in a significant reduction in FBPA activity in treated
lysates (94 and 2.1 milliunits/mg in extracts from bacteria
treated with 50 and 100 g/ml of HAMLET, respectively).
Similar to its inability to inhibit FBPA activity in vitro (Fig.
5A), OA had no inhibitory activity on FBPA activity in this
assay at the concentrations present in the HAMLET com-
plex (396 milliunits/mg at 12.5 g/ml OA). The results sug-
gest that HAMLET can traverse the membrane and access
the glycolytic machinery associated with the inner leaflet of
the membrane (16), which ALA cannot access.
Discussion
In this study, we show for the first time that the antimicrobial
molecule, HAMLET, targets glycolysis as part of its antibacte-
rial activity. Although this study was limited to the bacterial
pathogen S. pneumoniae, the results are likely more generally
applicable to Gram-positive bacteria. HAMLET is known to
have direct bactericidal activity against several Gram-positive
organisms as well as having the ability to sensitize a broader
array of both Gram-positive and Gram-negative organisms to
antibiotics (7, 11, 12). In all of these organisms, HAMLET treat-
ment induces identical initial changes, such as membrane
depolarization and ion transport, suggesting a conserved acti-
vation pathway. Based on this pathway conservation and the
fact that the pneumococcal targets identified in this study are
highly conserved between bacterial species, it is likely that the
mechanisms described in this study are also present in other
HAMLET-sensitive bacteria. This is interesting from several
perspectives.
As HAMLET also targets glycolysis in tumor cells (but not in
healthy cells (6, 17)), this suggests a conserved mechanism that
induces death in such diverse cells as bacteria and eukaryotes.
Although the specific glycolytic enzymes targeted byHAMLET
in this study (FBPA and GAPDH) and the study by Storm et al.
(6) (hypoxia-inducible factor 1, hexokinase, and 6-phospho-
2-fructokinase/fructose-2,6-bisphosphatase) were not identi-
cal, this merely emphasizes the complexity and potential diver-
gence through evolution of glycolytic regulation. In eukaryotes,
glucose is imported primarily through GLUT transporters,
which renders the hexokinase especially prone to regulation by
glucose levels in the blood in conjunction with glucose-6-phos-
phate levels in the cell. Also, the irreversible enzyme phospho-
Figure 5. HAMLET and ALA inhibit FBPA and GAPDH activity. Recombinant FBPA (A) or GAPDH (B) was preincubated with buffer alone or decreasing
concentrationsofHAMLET,ALA,OA, ormouse IgG for 15min.At this time, themixtureswereadded to reactionbuffer, the reactionwas startedbyaddingNADH
(for FBPA activity) andNAD (for GAPDH activity), and activity wasmonitored by a decrease and increase, respectively, in the absorbance at 340 nm. The results
arepresentedas thepercentageactivity comparedwith thebuffer-alone control. All results represent three individual experimentswithduplicate samples and
are presented as themeanwith error bars representing the S.D. Statistical analysis was performed using Student’s unpaired t test (*, p 0.05; **, p 0.01; ***,
p 0.001; ns, nonsignificant).
Figure 6. HAMLET inhibits FBPA activity in whole cells. D39 pneumo-
cocci were exposed to buffer alone (D39), ALA (100g/ml), HAMLET (50 or
100 g/ml), or OA (12.5 g/ml) for 10 min; bacterial cells were washed in
precooled buffer; and pneumococcal lysates were produced at 4 °C and
tested for FBPA activity presented as the breakdown of NADH at 340 nm
over time. The results represent three individual experiments with dupli-
cate samples and are presented as the mean (center line) with S.D.
depicted as the hatched lines surrounding the center line. Statistical analy-
sis was performed by comparing the enzymatic activity (in milliunits/mg
of lysate) over the first 10 min with Student’s unpaired t test (**, p 0.01
when comparing D39 lysate with lysate in the presence of 50 g/ml HAM-
LET; ***, p 0.001 when comparing D39 lysate with lysate in the presence
of 100 g/ml HAMLET).
Pneumococcal glycolysis inhibition by HAMLET
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fructokinase is regulated both by its substrate and cAMP levels
in the cell.
In Gram-positive bacteria, regulation is somewhat different.
The majority of glucose enters cells through carbohydrate
phosphoenolpyruvate:phosphotransferase (PTS) systems, where
glucose upon import is phosphorylated directly into glucose-6-
phosphate, thus circumventing hexokinase (18, 19). Regulation
of hexokinase therefore is of less importance. Instead, compo-
nents of the PTS system, such as HPr, as well as metabolites,
such as fructose-2,6-bisphosphate and glucose-6-phosphate,
regulate catabolic activity through transcriptional regulation of
genes using the major transcription factor CcpA (20). Both
HAMLET targets in this study, FBPA and GAPDH, are central
and essential enzymes in glycolysis in many bacterial species,
including pneumococci, and at least GAPDH’s function is reg-
ulated indirectly through CcpA and, at least in Staphylococcus
aureus, through the CcpA-dependent factor GapR (21, 22).
Although the regulatory framework is different in eukaryotes
and bacteria, HAMLET still targets glycolysis in both systems,
and it is possible that findings from the less complex bacterial
system can provide leads to potentialmechanisms involved also
in tumor cell death, and vice versa.
Furthermore, glycolysis as a target for tumor cell death has
become a topic of rising interest during the last couple of years
with the renaissance of theWarburg effect and its role in cancer
metabolism (23, 24). Otto Warburg described already in the
1920s that tumor cells are more glycolytically active than
healthy cells and showed that tumor cells exhibited increased
fermentation rather than aerobic respiration evenwhen oxygen
was present in abundance (aerobic glycolysis) (25, 26). Interfer-
ence with glycolysis would provide a selective advantage in tar-
geting tumor cells and is therefore a topic of great interest (27,
28). Inhibition of glycolysis by compounds such as 2-deoxyglu-
cose can inhibit growth of tumor cells, and its therapeutic
potential has been investigated in the treatment of certain solid
tumors (29, 30). Targeting glycolysis and its central enzymes
could also be effective for a multitude of bacterial species, such
as S. pneumoniae, that produce energy primarily from glycoly-
sis and fermentation (9, 31). Based on the structural and func-
tional differences of glycolytic enzymes between eukaryotes
and bacteria, especially with regard to FBPA (32, 33), screening
for potential molecules that target the activity of bacterial
FBPAs from several different species has been conducted in
vitro (34–37), but no such efficacy tests have so far been done
using whole bacteria. The known difference in structure
between eukaryote and prokaryote FBPA and an evolutionary
divergence inGAPDHgenes betweenmost eukaryotes andbac-
teria (38) suggest an explanation for the specific targeting of
these enzymes by HAMLET only in bacteria. The structural
motifs involved in HAMLET binding and its ensuing inhibition
of enzymatic activity are not known but are worthy of future
study, as they could provide clues for improved future thera-
peutic strategies, especially taking into account the high level of
conservation of glycolytic enzymes in bacteria affected by
HAMLET treatment.
Pneumococci lack the Krebs cycle and oxidative phosphory-
lation, and thus, the absolutemajority of ATP is produced from
glycolysis and fermentation of carbohydrates obtained from the
harsh environment of the host (31). Engagement primarily of
glycolysis is also true for many other facultative anaerobes,
many of which are sensitive to HAMLET’s direct bactericidal
effects or its ability to potentiate the activity of antibiotics (7).
These carbohydrates enter the bacterial cells through their
many and effective transport systems and eventually feed into
glycolysis. One of the vital roles of ATP is to maintain a polar-
izedmembrane, throughATP-driven transporters that extrude
or import ions, such as sodium, potassium, hydrogen, and cal-
cium, to retain a gradient over the membrane, resulting in the
production of an optimal membrane potential and proton
motive force. These gradients are then used to promote trans-
port of substrates, volume regulation, and other aspects of cell
function and integrity.
The mechanism of HAMLET-induced death of tumor cells
and bacteria is not fully characterized. However, we know that
HAMLET causes depolarization of the bacterial andmitochon-
drialmembranes and thatHAMLET-induced death requires an
influx of calcium in both systems (5, 8, 10). By inhibiting ATP
production from glycolysis, it is likely that HAMLET sensitizes
the bacteria by disrupting their ability to maintain membrane
polarity and specific ion gradients that, when dissipated, will
activate a downstream cascade of signaling, including kinase
and protease activity, that results in apoptosis-like morpholog-
ical features in pneumococcal cells (10). Additionally, reduced
ATP production also has the potential to both increase the
membrane permeability to antibiotics as a result of dissipation
of membrane polarity and may also decrease activity of drug
efflux pumps. These processes, combined, could explain the
increased activity of antibiotics in pneumococci as well as other
bacteria treated with sublethal doses of HAMLET, leading to
accumulation or increased association of antibiotics with bac-
terial cells (11, 12).
This study emphasized a crucial role of the protein compo-
nent of the HAMLET complex. In this study, we found that the
protein component per se is crucial for the glycolytic inhibition.
Both HAMLET and native ALA effectively inhibited the activ-
ity of both FBPA and GAPDH in vitro, whereas OA had no
activity. However, in most mechanistic studies performed to
date, we and others have shown that the oleic acid component
alone has the ability to induce bactericidal activity, just like
HAMLET, albeit at a higher concentration than found within
the HAMLET complex (see Fig. 1 for death induction and Refs.
39 and 40). A better understanding of the role of the lipid and
protein components of the HAMLET complex during bacterial
death or for increased activity during combination treatment
with antibiotics is therefore of great interest. The prior studies
indicate that HAMLET provides a way to effectively solubilize
and/or present the lipid to targets in the bacterial cell, most
likely the bacterial membrane. This effect is not confined to
oleic acid, as it has been shown that active HAMLET complex
can bemadewith other long-chained, unsaturated fatty acids in
the cis-configuration, such as vaccenic (C18:1 cis-11) linoleic
(C18:2 cis-9, 12), and linolenic acid (C18:3 cis-9, 12, 15) (41).
These fatty acids, as well as other shorter-chained fatty acids,
have long been known to have general bacteriostatic or bacte-
ricidal activity in and of themselves against several bacterial
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species (42), albeit at higher concentration than found in the
HAMLET complex.
At the same time, HAMLET’s effect on cell membrane polar-
ity and ion transport is reminiscent of other antimicrobial pep-
tides, such as defensins, lantibiotics, and some antibiotics of the
lipopeptide and glycopeptide classes. These agents associate
directly with the bacterial membrane to induce lysis, and some
peptides have been suggested to translocate into the cytoplasm
and have intracellular targets (43, 44). However, they also target
cell wall and peptidoglycan biosynthesis through direct inhibi-
tion of biosynthetic enzymes or binding to lipid II or bactopre-
nol-coupled cell wall precursors (45–48). The identified cell
wall targets of these antimicrobial peptides, such as MraY,
MurM, PBP2, LytR, and others, are conserved in pneumococci
(49, 50), but their role in HAMLET-induced death is not
known. Preliminary studies in our laboratory have shown an
initial interaction of HAMLETwith the pneumococcal cell wall
that appears to be required for subsequent downstream effects.
The role of these interactions both in HAMLET’s bactericidal
activity and in HAMLET translocation into the bacterial cell
will be of great interest for future studies.
As ALA had no activity when added exogenously, this sug-
gested that only when ALA is bound to OA in the correct con-
formation does it have activity, which is most likely correlated
with its ability to associate with membranes (51) that promote
internalization into the bacteria, similar to some other antimi-
crobial peptides (43). This is very similar to the internalization
of HAMLET into tumor cells (4), where HAMLET is found to
co-localize primarily with mitochondria. The efficiency of
internalization could not be determined in this study, as intra-
cellular visualization of HAMLET could not be observed
directly due to membrane association. Still, considering that
the IC50 in vitro of both FBPA and GAPDH was 1–2 g/ml
(60–120 nM), which was 50–100 times lower than the concen-
tration added exogenously, this provides a physiological possi-
bility that inhibitory amounts ofHAMLETwill reach its targets.
Additionally, the inhibitory effect of HAMLET was stronger
when HAMLET was added exogenously to pneumococci than
when added in combination with each enzyme alone in vitro. It
has been shown by MS analysis after in-solution digestion that
the glycolytic enzymes in pneumococci bind to each other and
are clustered together in a complex associated with the pneu-
mococcal membrane (52, 53). Thus, the binding of HAMLET
simultaneously to both FBPA and GAPDH present in a glyco-
lytic complex inside the bacterial cellmay lead tomore effective
inhibition of glycolysis than the interaction with either enzyme
alone in vitro.
As both FBPA and GAPDH are essential proteins in pneu-
mococci (54, 55) as well as other organisms (56–59), we were
not able to producemutants lacking one or the other protein to
better understand themechanistic aspects of HAMLET’s inter-
actionwith either enzyme inside the cells and the impact of that
interaction on glycolysis inhibition. As we have also been
unable over the years to produce HAMLET-resistant bacterial
mutants in the laboratory, this approach to gain a better under-
standing of the mechanisms involved in glycolysis inhibition
was also not possible.
In conclusion, this study shows that HAMLET’s bactericidal
activity is partly dependent on inhibition of glycolysis and ATP
production, similar to what has been described in tumor cells.
HAMLET inhibits ATP production from glycolysis by entering
the bacterial cell and interactingwith and inhibiting the activity
of the glycolytic enzymes FBPA and GAPDH. HAMLET’s
inhibitory effect on glycolysis in whole cells is associated with
the ALA component of the complex, as OA had no effect on
either ATP production in whole cells or glycolysis enzyme inhi-
bition either in vitro or in whole cells. This is different from
most other studies that have identified oleic acid as the cyto-
toxic component of the complex. Still, the lipid component of
the complex was required for its inhibitory activity in whole
bacterial cells, emphasizing the role of both ALA and oleic acid
in the bactericidal mechanism. Agents that inhibit glycolysis
and other energy-producing systems in bacterial cells represent
a novel class of antimicrobial agents in this era of rapidly
increasing antibiotic resistance development. Importantly, they
offer novel and promising therapeutic potential against targets
where there are no existing resistant mechanisms.
Experimental procedures
Reagents
Protein markers were from Thermo Fisher Scientific, and
enhanced chemiluminescence substrate was from GE Health-
care. Plasmid purification reagents, expression vectors, nickel-
nitrilotriacetic acid–agarose, and anti-RGS-His antibody were
from Qiagen (Valencia, CA). Anti-ALA antibody was from
Abcam (Cambridge, UK). Horseradish peroxidase (HRP)-con-
jugated anti-IgG antibody andmagnetic Dynabeads conjugated
with streptavidin or histidine were from Invitrogen, Inc. Bacto-
Todd Hewitt medium and Bacto-yeast extract were from BD
Biosciences. Remaining reagents were from Sigma.
HAMLET was produced as described (1) by complexing
EDTA-treated ALA, purified from human milk, with oleic acid
on an anion-exchange matrix (see Fig. S4 for the staining pat-
tern of HAMLET and ALA after separation by SDS-PAGE).
Lipid content of the HAMLET batch used was tested with the
free fatty acid quantitation kit (Sigma), resulting in a stoichiom-
etry of 6.1 molecules of oleic acid per molecule of ALA, repre-
senting 10.8% of the complex (w/w).
Bacterial strains
The bacterial strains, plasmids, and primers used for the
study are listed in Table 1. S. pneumoniae strain D39 (60) was
used throughout the study. Pneumococciwere stored at80 °C
in the presence of 15% glycerol and grown at 37 °C in Todd-
Hewitt broth supplemented with 0.5% yeast extract (THY) or
on tryptic soy agar supplemented with 5% sheep blood, as
appropriate.
Escherichia coliXL1-Blue (Stratagene/Agilent Technologies,
Santa Clara, CA) was used for cloning of recombinant protein
constructs, and E. coli M15 (Qiagen, Valencia, CA) was used
to express recombinant proteins. Ampicillin (100 g/ml) and
kanamycin (50 g/ml) were added to Luria–Bertani (LB)
growth medium and LB agar plates to provide required selec-
tion, when appropriate.
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Pneumococci were grown to an optical density (OD600 nm)
of 0.6, pelleted, and washed twice in PBS, pH 7.2, by centrif-
ugation at 8,000 g for 2 min. Bacteria were resuspended in
PBS and preincubated with buffer alone, glucose, or 2-de-
oxyglucose for 15 min prior to the addition of HAMLET,
ALA, or oleic acid. HAMLET and ALA are soluble in buffer
up to concentrations of 50 mg/ml, whereas solubility of OA
is limited in water. To improve the solubility of OA, OA was
first dissolved in ethanol at a concentration of 10 mg/ml, and
this stock solution was used to further dilute OA in PBS for
experiments. After 1 h, 10-fold dilutions of bacterial suspen-
sion were plated on blood agar plates. Bacterial viability was
measured by plate counts from plates grown overnight at
37 °C and measured as cfu/ml.
Expression of recombinant proteins
Recombinant DLDH was produced from M15 E. coli har-
boring the pQE30 plasmid containing the full-length dldh
sequence (SPD_1026 in the D39 genome (61)), as described
(62). The fba (SPD_0526), gapA (SPD_1823), and gki
(SPD_0580) genes were amplified by PCR using primer pairs
Fba-pQE-F/Fba-pQE-R, Gap-pQE-F/Gap-pQE-R, or Gki-
pQE-F/Gki-pQE-R, respectively (Table 1) and chromosomal
DNA from S. pneumoniae D39 (27) as template. The ampli-
fied fragments were cloned into the pQE30 expression vec-
tor and transformed into XL-1 Blue cells. Clones carrying the
insert of interest were selected on LB agar containing ampi-
cillin (100 g/ml) and verified by restriction digestion and
sequencing of purified plasmid. Verified plasmids were then
transformed into E. coli M15 cells for protein expression.
Overnight cultures of M15 cells carrying each of the four
enzymeswere used to seed fresh cultures, and the cultures were
grown shaking at 37 °C to an OD600 nm of 0.5. Expression of
plasmid-borne protein sequences was induced with 1 mM iso-
propyl 1-thio--D-galactopyranoside for 4 h, and the overex-
pressed proteins were purified from bacterial lysates by affinity
chromatography using nickel-nitrilotriacetic acid–agarose
(Qiagen) according to the manufacturer’s instructions. The
proteinswere analyzed by SDS-PAGE (see Fig. S4) andWestern
blotting and were quantified using the BioTek Synergy 2 plate
reader with the Take3 microdrop addition (Biotek, Winooski,
VT).
Binding assays andWestern blotting
For binding assays in solution, recombinant His-tagged
enzymes were produced as described above, and 3.25 g of
rFBPA and 6.5 g of the remaining three enzymes was incu-
bated with 5g of HAMLET in a total volume of 0.5 ml. After a
30-min incubation at room temperature, 20 l of His-coupled
magnetic beads (Dynabeads, Invitrogen) were added, the beads
were collected by a magnet and washed five times in PBS, and
beads were boiled and supernatant was run by gel electropho-
resis and blotted as below.
Protein sources (1–4 g of purified enzymes or 10 g of
bacterial lysate, as determined by the Bradford assay) were run
on 4–12% BisTris gels (Invitrogen) under denaturing condi-
tions, and the gels were electroblotted to a nitrocellulose mem-
brane (GEHealthcare) using transfer buffer (Invitrogen) for 1 h.
Blotted membranes were blocked in PBS containing 0.05%
Tween-20 (PBS-T) with 2.5% skimmilk for 1 h at room temper-
ature andwashed three times with PBS-T (PBS containing 0.2%
Tween 20). To detect HAMLET binding in solution, mem-
branes were incubated both with anti-ALA antibody (1:500
dilution) to detect the capture of HAMLET by the recombinant
proteins andwith anti-His antibody (1:1,000 dilution) to ensure
the capture of the recombinant protein by the beads. The blots
were further incubated with rabbit-anti-mouse IgG (His blot)
or goat-anti-rabbit IgG (ALA blot) antibody conjugated with
HRP for detection. Detection of bands on each blot was done
using a GelDoc EZ system (Bio-Rad) with the Image Lab 6 soft-
ware, set to automatic mode for optimal capture of signal in
each blot image.
To determine binding on solid phase, membranes were incu-
bated with biotinylated HAMLET or ALA (5g/ml), washed in
PBS-T, and further incubated with streptavidin conjugated
with HRP (1:5,000 dilution in PBS-T) for 1 h at room tempera-
ture. After washing, the membrane was developed as described
above.
Table 1
Strains and primers used in this study
Description Reference
Strains
D39 Pneumococcal serotype 2 WT strain Ref. 60
XL-1 Blue E. coli strain used for cloning Stratagene




pQE30 E. coli expression vector Qiagen Inc.
pSH-rDLDH pQE30 vector containing fullength dldh sequence Ref. 62
pHH-rFba pQE30:: XbaI-HindIII Fba-pQE-F/R PCR product This study
pHH-rGapA pQE30::BamHI-HindIII Gap-pQE-F/R PCR product This study
pHH-rGki pQE30::BamHI-PstII Gki-pQE-F/R PCR product This study
Primers
Fba-pQE-F TGCTCTAGAGGGTGCTGCTAAATACA This study
Fba-pQE-R CCCAAGCTTGTGTTAACGTTAACTTTGG This study
Gap-pQE-F CGCGGATCCGTAGTTAAAGTTGGTATTAACG This study
Gap-pQE-R CCCAAGCTTTTATTTAGCAATTTTTGC This study
Gki-pQE-F CGCGGATCCATGAGTCAAAAGATTATTGG This study
Gki-pQE-R CCCCTGCAGTTATTGCAATACAAGTGATG This study
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HAMLET (1mg in a 200-l volume)was sequentially labeled
with NHS-LC-Diazirine, a UV-excitable cross-linker, and
amine-reactive biotin from the EZ-link Sulfo-NHS-LC biotiny-
lation kit (both from Pierce/Thermo Scientific) according to
the manufacturer’s instructions. After quenching with 10 mM
Tris-HCl, pH 8, to terminate the reaction, HAMLET carrying
biotin and cross-linker was purified over a Zeba desalting col-
umn, and the final protein concentrationwas determined using
a BioTek Synergy 2 plate reader with the Take3 microdrop
addition (Biotek).
D39 pneumococci (10 ml) were grown in THY to an
OD600 nm of 0.6, and the bacteria were pelleted by centrifuga-
tion at 1,500  g for 10 min, washed once in PBS, and resus-
pended in 900 l of PBS. Bacteria were lysed by the addition of
100 l of 4% sodium deoxycholate and incubation for 5 min at
room temperature, and the resulting lysate was purified
through a Zeba desalting column (Thermo Fisher Scientific).
The protein concentration of the final eluate was determined as
above.
Bacterial lysate (1 mg in 100 l) was incubated with tagged
HAMLET carrying cross-linker and biotin (12.5g in 50l) for
30 min on ice. Proteins in the vicinity of HAMLET were cross-
linked by exposing the sample to UV light (365 nm) for 10 min,
and the reaction was incubated with 50 l of Streptavidin-cou-
pled magnetic beads (Dynabeads, Invitrogen), collected by a
magnet, and washed five times in PBS. Captured proteins were
identified by nano-LC-MS (Prot Tech, Norrisville, PA).
Enzyme assays
ForATPand lactate production, bacteriawere grown inTHY
to an OD600 nm of 0.6, pelleted, washed twice in PBS by centrif-
ugation at 8,000  g for 2 min, and resuspended in PBS to the
original volume. After treatment, bacterial ATP production
was determined using the ATP determination kit (Invitrogen,
Thermo Fisher Scientific) according to the manufacturer’s
instructions with slight modification. To determine intracellu-
lar ATP concentrations, 10l of bacteria were added to 90l of
reaction buffer containing 0.5% Triton X-100 required to lyse
the bacteria, and the luciferin conversion was measured by
chemiluminescence as a measure of ATP in the sample using a
Synergy 2 plate reader (Biotek). Triton X-100 was used to lyse
bacteria, as both SDS and deoxycholate inhibited the luciferase
in the assay as has been described previously (63).
Lactate produced by the bacteria was determined essentially
as described (64) by measuring the production of NADH in
Reaction 1.
NAD  lactate 7 NADH  H  pyruvate
Reaction 1
Bacteria grown as described above were treated, 250 l of bac-
teria were pelleted per sample, and the supernatant containing
lactate was immediately saved at20 °C until further analysis. To
determine lactate, 100l of samplewasmixedwith 200l of reac-
tion buffer (100mM potassium phosphate (pH 9), 320 mM phenyl
hydrazine, 2.4 mM NAD, and 2 units/ml L-lactate dehydroge-
nase), and the absorbance of formedNADHwasmeasured at 340
nm in a Synergy 2 plate reader (Biotek). The concentration of lac-
tate was determined from a standard curve of known concentra-
tions of sodium lactate determined on the same plate.
FBPA (EC 4.1.2.13) activity was determined as described (65)
by measuring the breakdown of NADH in the linked reaction
presented in Reactions 2–4, where FBPA catalyzes Reaction 2,
and Reactions 3 and 4 are catalyzed by triose-phosphate
isomerase (EC 5.3.1.1) and -glycerophosphate dehydrogenase
(EC 1.1.1.8), respectively.
D-Fructose1,6-phosphate 7 glycerone phosphate
 D-glyceraldehyde3-phosphate
D-Glyceraldehyde3-phosphate 7 glycerone phosphate
Glycerone phosphate  NADH  H7
sn-glycerol3-phosphate NAD
Reactions 2–4
Recombinant FBPA was mixed with reaction buffer (50 mM
Tris-HCl (pH 8), 100 mM KAc, 0.4 mM NADH, 5 mM fructose
1,6-phosphate, 0.6 units each of triose-phosphate isomerase
and-glycerophosphatedehydrogenase).Theactivitywasmea-
sured as a decrease in absorbance at 340 nm in a Synergy 2 plate
reader (Biotek) and quantified in units (conversion of substrate
in mol min1) per mg of enzyme using an extinction coeffi-
cient of 6.22 mM1 cm1 of NADH at 340 nm. For inhibition
studies, recombinant FBPAwas preincubatedwith various con-
centrations of HAMLET or other potential inhibitor com-
pounds for 15 min prior to initiating the reaction.
GAPDH (EC 1.2.1.12) activity was measured according to
Cori et al. (66) by measuring the production of NADH in Reac-
tion 5.
D-Glyceraldehyde3-phosphate  NAD  Pi7
3-phospho-D-glyceroyl phosphate NADH H
Reaction 5
Recombinant GAPDH was mixed with reaction buffer (15
mM potassium pyrophosphate and 30 mM sodium arsenate set
to pH 8.5 with 10% phosphoric acid, 1.25 mM NAD, 3.3 mM
DTT, and 1 mM D-glyceraldehyde-3 phosphate). Free D-glycer-
aldehyde 3-phosphate was prepared from a diethyl acetate bar-
ium salt, where the diethyl acetate barium was cleaved off on a
DOWEX resin as described by the manufacturer (Sigma, prod-
uct G5376). The activity was measured as an increase in absor-
bance at 340 nm in a Synergy 2 plate reader (Biotek), and activ-
ity was quantified in units/mg of enzyme using an extinction
coefficient of 6.22 mM1 cm1 of NADH at 340 nm. For inhi-
bition studies, recombinant GAPDH was preincubated with
various concentrations of HAMLET or other potential inhibi-
tor compounds for 15 min prior to starting the reaction.
GK (EC 2.7.1.1) was determined by measuring the produc-
tion of NADH in the linked reaction presented in Reactions 6
and 7, where glucokinase catalyzes Reaction 6 and Reaction 7 is
catalyzed by glucose-6-phosphate dehydrogenase (EC 1.1.1.49)
(67).
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D-Glucose  ATP 7 D-glucose6-phosphate  ADP
D-Glucose6-phosphate  NAD7
6-phospho-D-glucono-1,5-lactone NADH H
Reactions 6 and 7
Recombinant GK was mixed with reaction buffer (50 mM
Tris-HCl (pH 7.4), 10 mM MgSO4, 20 mM NAD, 1 mM D-glu-
cose, 1 mM ATP, and 10 units/ml glucose-6-phosphate dehy-
drogenase). The activity was measured as an increase in absor-
bance at 340 nm in a Synergy 2 plate reader (Biotek), and
activity was determined in units/mg of enzyme using the
extinction coefficient of 6.22 mM1 cm1 of NADH at 340 nm.
For inhibition studies, recombinant GK was preincubated with
various concentrations of HAMLET or other inhibitors for 15
min prior to starting the reaction.
Recombinant DLDH activity was measured as the oxidation of
NADH in the presence of 6,8-thioctic acid amide (lipoamide),
visualized as decreased absorbance at 365 nm according to Reac-
tion 8 as described (62). Activity was determined in units/mg of
enzyme using the extinction coefficient of 3.29 mM1 cm1 of
NADHat 365nm. For inhibition studies, recombinantDLDHwas
preincubated with various concentrations of HAMLET or other
inhibitors for 15min prior to starting the reaction.
NADH  H  lipoamide 7 NAD  dihydrolipoamide
Reaction 8
Statistical analysis
Group comparisons were examined with the unpaired
Student’s t test using Prism version 8 software (GraphPad
Software, Inc., La Jolla, CA).
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